Align Technology
ALGN
$181.49
+7.61%
Align Technology is a global medical device company that designs, manufactures, and markets the Invisalign system of clear aligners and the iTero intraoral scanner. It is the dominant market leader in the clear aligner segment, controlling over 90% of the market and supported by a global network of over 230,000 trained dental professionals. The current investor narrative is shaped by activist involvement and a debate over unlocking shareholder value, as evidenced by a significant position from Elliott Management reported in March 2026, which has fueled speculation about potential strategic changes to address what some perceive as an undervalued stock despite the company's entrenched competitive position.…
ALGN
Align Technology
$181.49
Related headlines
ALGN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Align Technology's 12-month outlook, with a consensus price target around $235.94 and implied upside of +30.0% versus the current price.
Average Target
$235.94
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$145 - $236
Analyst target range
Analyst coverage for ALGN appears limited based on the provided data, with only 5 analysts contributing to estimates for revenue and EPS, suggesting coverage may be sparse or the data is incomplete. The consensus revenue estimate for the period is $4.89 billion, with a narrow range from $4.84 billion to $4.94 billion, indicating high conviction on the top-line forecast. The average EPS estimate is $15.77, bracketed by a low of $15.57 and a high of $15.98. While explicit price targets and a Buy/Hold/Sell distribution are not provided in the dataset, recent institutional rating actions show a generally positive but cautious bias. Notable actions include Barclays upgrading from Equal Weight to Overweight in March 2026 and HSBC upgrading from Hold to Buy in February 2026, while firms like Morgan Stanley and UBS maintain Neutral or Equal Weight ratings. This pattern of recent upgrades, coupled with the activist investor news, suggests a building bullish sentiment among some analysts, though the lack of a broad consensus target price implies remaining uncertainty or data limitations for a precise upside calculation.
Bulls vs Bears: ALGN Investment Factors
The bull and bear cases for ALGN are sharply defined, with the bull side currently holding stronger near-term evidence due to the potent combination of activist catalyst and a discounted forward valuation anticipating an earnings recovery. The bear case is grounded in concerning fundamental trends like slowing growth and margin pressure. The single most important tension in the investment debate is whether the activist-driven strategic actions and expected earnings rebound (forward P/E 14.2x) can successfully overcome the underlying challenges of market saturation and margin compression that have led to significant stock underperformance. The resolution of this tension—specifically, the company's ability to re-accelerate profitable growth—will determine if the stock re-rates higher or remains stuck in its volatile trading range.
Bullish
- Activist Catalyst with Elliott Management: The reported large position by activist investor Elliott Management in March 2026 provides a powerful, non-fundamental catalyst for unlocking shareholder value. This external pressure increases the probability of strategic changes, such as capital return or operational improvements, to address the stock's perceived undervaluation relative to its historical trading multiples.
- Strong Forward Earnings Recovery Priced In: The market is pricing in a significant earnings rebound, with a forward P/E of 14.20x based on an estimated EPS of $15.77. This is a substantial discount to the trailing P/E of 27.59x and suggests a 49% compression in the earnings multiple, implying high confidence in near-term profit growth and potentially creating a valuation floor.
- Dominant Market Position & Robust Profitability: Align controls over 90% of the clear aligner market, supported by a network of 230,000+ trained professionals. This dominance underpins solid profitability, with a trailing net margin of 10.17% and robust gross margins of 68.33%, providing a wide economic moat and significant cash generation capability, evidenced by $593.2M in TTM free cash flow.
- Exceptionally Strong Balance Sheet: The company carries minimal financial risk with a debt-to-equity ratio of 0.028 and a healthy current ratio of 1.36. This fortress balance sheet provides ample flexibility to navigate economic cycles, fund growth, return capital to shareholders, or execute strategic initiatives prompted by activist involvement.
Bearish
- Sluggish Revenue Growth & Market Saturation: Revenue growth is modest, with Q4 2025 YoY growth at just 5.26%. The Clear Aligner segment, representing over 75% of revenue, may be facing market saturation pressures after years of dominance, raising questions about the company's ability to return to high double-digit growth rates that previously justified premium valuations.
- Gross Margin Compression & Pricing Pressure: Q4 2025 gross margin of 65.69% showed significant compression from 70.03% in Q4 2024. This 434 basis point decline indicates potential pricing pressure, unfavorable product mix, or increased competition, which could threaten the company's high-profit business model if the trend persists.
- High Volatility & Severe Underperformance: The stock has a beta of 1.67, making it 67% more volatile than the market, and has significantly underperformed the S&P 500 by over 27 percentage points in the past year (-6.11% vs. +20.95%). This high volatility and weak relative strength make it a riskier holding, especially in market downturns.
- Valuation Still High on Trailing Basis: Despite the discount to its own history, the trailing P/E of 27.59x remains elevated for a company with mid-single-digit revenue growth. The PEG ratio of 51.77 is extremely high, indicating the stock price is not justified by its current growth rate, posing a risk of further multiple compression if growth disappoints.
ALGN Technical Analysis
The stock is in a clear recovery trend from its 52-week lows but remains well below its yearly highs, positioning it in a volatile consolidation phase. Over the past year, the stock has declined -6.11%, significantly underperforming the S&P 500, which gained 20.95%. With a current price of $175.71, it is trading at approximately 74% of its 52-week range ($122 to $208.31), indicating it is closer to the midpoint than the extremes, suggesting a lack of decisive directional momentum over the longer term. The 1-month return of +7.44% and 3-month return of +5.61% show a recent positive shift, contrasting sharply with the negative 1-year performance, signaling a potential trend reversal or a significant relief rally from oversold conditions. The stock's beta of 1.67 confirms it is approximately 67% more volatile than the broader market, which is critical for risk assessment. Key technical levels are clearly defined, with the 52-week high of $208.31 acting as formidable resistance and the 52-week low of $122.00 providing a distant but critical support floor. A sustained breakout above the $200 level would signal a resumption of the long-term uptrend, while a breakdown below the recent May lows near $155 could indicate a retest of the 52-week low, given the stock's high volatility and relative weakness versus the market over the past year.
Beta
1.67
1.67x market volatility
Max Drawdown
-39.7%
Largest decline past year
52-Week Range
$122-$208
Price range past year
Annual Return
-6.6%
Cumulative gain past year
| Period | ALGN Return | S&P 500 |
|---|---|---|
| 1m | +6.9% | -1.7% |
| 3m | +6.4% | +13.7% |
| 6m | +16.3% | +9.2% |
| 1y | -6.6% | +20.7% |
| ytd | +16.3% | +9.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALGN Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $1.047 billion representing a 5.26% year-over-year increase. However, growth has been uneven across recent quarters, with Q4 revenue up sequentially from Q3's $995.7 million, indicating some recovery momentum. The Clear Aligner segment, at $794.3 million for the period, remains the primary driver, significantly larger than the Scanners and Services segment at $200.9 million. The company is solidly profitable, with Q4 2025 net income of $135.8 million and a trailing twelve-month net margin of 10.17%. Gross margins remain robust at 68.33% on a trailing basis, though the Q4 2025 gross margin of 65.69% showed some compression compared to the 70.03% in Q4 2024, reflecting potential pricing pressures or product mix shifts. The balance sheet is exceptionally strong with minimal financial risk, evidenced by a very low debt-to-equity ratio of 0.028 and a healthy current ratio of 1.36. The company generates substantial cash, with trailing twelve-month free cash flow of $593.2 million, providing ample internal funding for growth initiatives and shareholder returns, as seen with ongoing stock repurchases. Return on equity of 10.13% is respectable, indicating efficient use of shareholder capital.
Quarterly Revenue
$1.0B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$593223000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALGN Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 27.59x, while the forward PE is significantly lower at 14.20x, indicating the market expects a substantial near-term earnings recovery. This forward multiple is derived from an estimated EPS of $15.77, suggesting the market is pricing in a significant earnings rebound, which aligns with the activist catalyst narrative. Compared to the provided industry averages, Align's trailing PE of 27.59x and Price-to-Sales (PS) ratio of 2.81x are not directly comparable without sector benchmarks, but the forward PE of 14.20x appears reasonable for a profitable market leader if growth expectations materialize. Historically, the stock's own valuation has compressed significantly from pandemic-era highs; for instance, its trailing PE has declined from peaks above 60x in early 2023 to the current 27.59x. The current trailing PE of 27.59x is below its multi-year average seen in the historical data (which frequently exceeded 40x), suggesting the stock is trading at a discount to its own historical valuation, potentially offering a value opportunity if the fundamental outlook improves.
PE
27.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~98x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Align's primary financial risk is not leverage but growth sustainability and margin preservation. Revenue growth has decelerated to 5.26% YoY in Q4 2025, and gross margin compressed by 434 basis points year-over-year in the same quarter. This raises concerns about the company's ability to maintain its high-profit model in a potentially saturating core market. While the balance sheet is strong (D/E 0.028), the company's valuation (trailing P/E 27.59x) remains dependent on a return to stronger growth, creating vulnerability if the expected earnings rebound (EPS $15.77) fails to materialize.
Market & Competitive Risks: The stock trades at a significant valuation premium to the market (P/E 27.59x vs. market average ~20x) while showing weak growth, creating a high risk of further multiple compression. Its high beta of 1.67 means it is highly sensitive to broader market downturns and sector rotations away from growth stocks. The recent activist involvement, while a catalyst, also introduces event risk; if Elliott Management's proposals are rejected or fail to create value, the stock could give up its recent gains. Furthermore, the company's >90% market share is both a strength and a risk, as it paints a target for competitors and could attract regulatory scrutiny.
Worst-Case Scenario: The worst-case scenario involves a failure of the activist catalyst to drive change, coupled with a continuation of margin compression and growth stagnation. This could trigger a wave of analyst downgrades from the recently upgraded positions. A broader market correction, amplified by the stock's high beta, could accelerate the decline. In this adverse scenario, the stock could realistically retest its 52-week low of $122, representing a potential downside of approximately -30.5% from the current price of $175.71. The historical max drawdown of -39.73% provides a precedent for such severe declines during periods of fundamental disappointment.